While the injections from Lilly and Novo have revolutionized the way obesity is treated, investors say pills are key to ...

Shares of Eli Lilly and Co. tumbled 12.8% in premarket trading Thursday, toward its biggest one-day selloff in 26 years, after the drug giant disclosed late-stage trial data for its oral weight-loss ...

Eli Lilly (LLY) stock plunges as Phase 3 trial data for the company's oral weight loss drug orforglipron overshadow better ...

Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...

Eli Lilly stock falls after new data on its weight-loss drug Orforglipron, ahead of scheduled second-quarter earnings.

Earnings, adjusted for one-time gains and costs, came to $6.31 per share. The results surpassed Wall Street expectations. The ...

In eagerly awaited results from a new study, the pharmaceutical company Eli Lilly reports that a pill its scientists ...

Eli Lilly has hoped its candidate weight loss pill would safeguard its lead in the obesity market, but new results may prove ...

Eli Lilly's pill, orforglipron, is one step closer to becoming the first new, needle-free alternative in the booming market ...

The company said it planned to seek Food and Drug Administration approval for the drug, orforglipron, before the end of the ...

In the first Phase 3 trial of its once-daily oral GLP-1 pill in people with obesity, drugmaker Eli Lilly said Thursday that ...